Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
Birgit Geoerger, Bruce Morland, Irène Jiménez, Didier Frappaz, Andrew D.J. Pearson, Gilles Vassal, Patricia Maeda, Jasmine Kincaide, U. Mueller, Sarah Schlief, Michael Teufel, Bart A. Ploeger, Adriaan Cleton, A. Chassot Agostinho, Lynley V. Marshall
Topics & Concepts
RegorafenibRefractory (planetary science)PharmacokineticsMedicineOncologySolid tumorPhase (matter)Internal medicineMaterials scienceCancerChemistryColorectal cancerOrganic chemistryComposite materialChemotherapy-related skin toxicityLung Cancer Treatments and MutationsNeuroblastoma Research and Treatments